Accenture reported a 7% revenue growth in the fourth quarter, surpassing guidance, but forecasts only 1–3.5% organic growth for fiscal year 2027. The company’s growth is supported by acquisitions, strong cash flow, and federal contracts, yet it faces margin pressures from AI-driven pricing declines and geopolitical challenges in the Middle East. Despite being a leader in the IT services sector, Accenture's outlook is clouded by AI disruption risks, prompting a cautious Sell rating. Smaller, more agile competitors may benefit if the sector's growth picks up again.
As of Oct 05, 2026 19:11 WIB, Accenture (ACN) shares are stable at USD 198.90 on Pluang, showing no change in the last day. The stock holds a significant market cap of $110.94 billion and offers a dividend yield of 3.28%. This steady trading contrasts with the cautious outlook highlighted in the news, underscoring the company's established position despite sector challenges.
Accenture plc reported strong quarterly results, prompting a valuation increase and signaling the start of a recovery with over 20% total return recently. Management projects 3–6% revenue growth, a 15.9–16.1% operating margin, and plans $5 billion in...
Accenture plc received a Hold rating due to its current valuation already reflecting a 3% organic growth forecast and unresolved risks related to AI. Despite strong Q4 managed services bookings and stable demand, the company faces ongoing pricing pre...
Accenture's stock was downgraded from buy to hold following a 70% rise in its share price and disappointing growth metrics. In Q4, revenue grew 6% year-over-year, but only 3% was organic growth, which is below inflation. The company's fiscal 2027 gui...
Accenture's stock fell nearly 60% from its peak amid fears that AI would reduce its consulting revenue, but it surged nearly 16% after a strong earnings report. Analyst Kevin McVeigh from UBS maintains a $275 price target, seeing 30% upside due to Ac...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
